头孢曲松治疗非危重社区获得性肺炎的剂量 (DC-CAP)
评估重症监护室外社区获得性肺炎头孢曲松用量的实用性随机试验
Aim: Demonstrate the equivalent efficacy and superior safety of Ceftriaxone 1 gram daily compared with Ceftriaxone 2 grams daily among hospitalized patients with community-acquired pneumonia who are not admitted to the intensive care unit.<p>
Hypothesis: Among hospitalized patients outside of the intensive care unit with community-acquired pneumonia who are prescribed Ceftriaxone, a dosage of 1 gram daily will be associated with an equivalent rate of clinical cure and fewer adverse events than a dosage of 2 grams daily.
研究概览
详细说明
This study will be a pragmatic trial in which prospectively enrolled patients will be randomly assigned to Ceftriaxone dosed either 1 gram or 2 grams daily. When a clinician in the emergency department or non-intensive care inpatient ward orders Ceftriaxone and selects 'community-acquired pneumonia' as the indication, the electronic health record software used at the study sites (Epic) will prompt the ordering clinician to opt into the study. No direct patient contact will occur.
研究类型
注册 (估计的)
阶段
- 第四阶段
联系人和位置
学习联系方式
- 姓名:Jonathan D Baghdadi, MD, PhD
- 电话号码:410-706-0066
- 邮箱:jbaghdadi@som.umaryland.edu
学习地点
-
-
Maryland
-
Baltimore、Maryland、美国、21201
- University of Maryland Medical Center
-
接触:
- Megan Dunning, MD
- 电话号码:410-328-8667
- 邮箱:mdunning@ihv.umaryland.edu
-
Baltimore、Maryland、美国、21201
- University of Maryland Medical Center - Midtown Campus
-
接触:
- Jonathan Baghdadi, MD, PhD
- 电话号码:410-225-8000
- 邮箱:jbaghdadi@som.umaryland.edu
-
Glen Burnie、Maryland、美国、21061
- UM Baltimore Washington Medical Center
-
接触:
- Stephanie Pires, PharmD
- 电话号码:410-787-4000
- 邮箱:Stephanie.Pires@umm.edu
-
Towson、Maryland、美国、21204
- University of Maryland St. Joseph Medical Center
-
接触:
- Rose Kohinke, PharmD
- 电话号码:410-337-1000
- 邮箱:Rose.Kohinke@umm.edu
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Evaluated in the emergency department or within 72 hours of hospitalization
- Prescribed Ceftriaxone for community-acquired pneumonia
Exclusion Criteria:
- Planned or present admission to an intensive care unit
- Respiratory failure requiring mechanical ventilation, non-invasive ventilation such as bilevel positive airway pressure, or high flow nasal cannula
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
有源比较器:Low Dose Ceftriaxone
Intravenous Ceftriaxone will be dosed 1 gram daily per institutional guidance for treatment of community-acquired pneumonia outside of the intensive care unit. |
Intravenous Ceftriaxone will be dosed 1 gram daily per institutional guidance for treatment of non-critical community-acquired pneumonia. |
|
有源比较器:Moderate Dose Ceftriaxone
Intravenous Ceftriaxone will be dosed 2 grams daily per institutional guidance for treatment of community-acquired pneumonia outside of the intensive care unit. |
Intravenous Ceftriaxone will be dosed at 2 grams daily per institutional guidance for treatment of community-acquired pneumonia. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Antibiotic escalation within 5 days of randomization
大体时间:The outcome will be assessed 5 days after enrollment
|
Defined by increasing the dose or frequency of Ceftriaxone, starting additional antibiotics not ordered concurrently with Ceftriaxone, or switching Ceftriaxone to an antibiotic with a broader spectrum up activity >24 hours after enrollment; antibiotic changes made on the calendar day of discharge in preparation for discharge alive from the hospital will not be considered escalation |
The outcome will be assessed 5 days after enrollment
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Time to stability
大体时间:The outcome will be assessed 90 days after enrollment
|
Time in days from randomization until stability defined by temperature < 38, heart rate < 100, respiratory rate < 24, oxygen saturation > 90%, systolic blood pressure ≥ 90, and return to baseline mental status based on Glasgow Coma Score over a 24-hour period |
The outcome will be assessed 90 days after enrollment
|
|
Clinical deterioration within 10 days of randomization
大体时间:The outcome will be assessed 10 days after enrollment
|
Defined by admission to an intensive care unit, mechanical ventilation, or in-hospital mortality on any hospital day, or supplemental oxygen >5 L after hospital day 3 during the index encounter |
The outcome will be assessed 10 days after enrollment
|
|
Ceftriaxone-associated toxicity within 10 days of randomization
大体时间:The outcome will be assessed 10 days after enrollment
|
Defined by new development of Hemoglobin < 10, elevated liver enzymes or or total bilirubin, clinically significant diarrhea (represented by Clostridioides difficile testing), or rash (represented by consult to dermatology) |
The outcome will be assessed 10 days after enrollment
|
|
Ranked composite outcome
大体时间:The outcome will be assessed 30 days after enrollment
|
Rank 1 (highest rank) = no antibiotic escalation, clinical deterioration, or Ceftriaxone-associated toxicity Rank 2 = antibiotic escalation without clinical deterioration or Ceftriaxone-associated toxicity Rank 3 = Ceftriaxone-associated toxicity without clinical deterioration Rank 4 = clinical deterioration without 30-day mortality Rank 5 = 30-day mortality |
The outcome will be assessed 30 days after enrollment
|
|
Duration of antibiotics
大体时间:The outcome will be assessed 90 days after enrollment
|
Defined as the total days of antibiotic therapy during the hospital encounter |
The outcome will be assessed 90 days after enrollment
|
|
Hospital length of stay
大体时间:The outcome will be assessed 90 days after enrollment
|
Duration of hospitalization in days |
The outcome will be assessed 90 days after enrollment
|
|
All-cause readmission
大体时间:The outcome will be assessed 90 days from enrollment
|
Readmission for any reason within 30 days of hospital discharge |
The outcome will be assessed 90 days from enrollment
|
|
In-hospital mortality
大体时间:The outcome will be assessed 90 days after enrollment
|
In-hospital death or discharge to hospice |
The outcome will be assessed 90 days after enrollment
|
|
Clostridioides difficile infection
大体时间:The outcome will be assessed 90 days after enrollment
|
Positive laboratory test for Clostridioides difficile within 30 days of randomization |
The outcome will be assessed 90 days after enrollment
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.